Kiyatec Inc. Achieves Prestigious CAP Accreditation and New York State Approval for 3D Predict™

GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec Inc., a leader in advancing patient-specific cancer diagnostics, proudly announces its laboratory’s accreditation by the College of American Pathologists (CAP) and receipt of New York State approval for its groundbreaking 3D Predict test. These achievements underscore Kiyatec’s commitment to delivering high-quality, innovative diagnostic solutions that support personalized cancer care.

The CAP accreditation, recognized as the gold standard in laboratory quality assurance, confirms that Kiyatec meets the highest standards of excellence in laboratory operations, ensuring accuracy and reliability in its patient-specific diagnostics. This accreditation is a testament to Kiyatec’s dedication to rigorous quality control and its mission to revolutionize cancer care. Additionally, Kiyatec’s laboratory is CLIA-certified (CLIA Certificate #42D2130169) and utilizes an Established CPT Code (0248U), further validating the clinical application and accessibility of its technology.

In addition to CAP accreditation, Kiyatec has received New York State approval for its 3D Predict tests. This milestone highlights the clinical validity and utility of these assays, which use live tumor cell analysis to forecast patient-specific responses to cancer therapies. Only Kiyatec’s proprietary 3D cell culture platform is supported by published, peer-reviewed evidence correlating therapeutic response predictions to actual patient outcomes, setting a new benchmark in functional precision oncology.

Furthermore, Kiyatec’s advancements have brought hope to patients with high-grade gliomas, including glioblastoma. These devastating cancers have seen little progress in therapeutic outcomes for decades. With 3D Predict™ Glioma, Kiyatec offers a groundbreaking tool that provides oncologists with actionable insights to guide treatment decisions, representing the first meaningful advancement in this area in years.

Eric Perreault, CEO of Kiyatec, said, “We’re thrilled to see our 3D Predict platform gaining this recognition. These approvals mean so much because they’re not just about validating our science – they’re about making a real difference in patients’ lives. I’m passionate about ensuring that more patients and their doctors have access to the personalized insights these tests provide, and this brings us one step closer to that goal.”

Kiyatec’s 3D Predict platform provides oncologists with actionable insights by accurately predicting how individual patients’ cancers will respond to specific therapies. This approach represents a paradigm shift in cancer diagnostics, moving from one-size-fits-all to truly personalized treatment planning.

About Kiyatec

Kiyatec is committed to advancing functional precision oncology with its proprietary 3D cell culture platform. By integrating science, technology, and clinical expertise, Kiyatec enables oncologists to deliver personalized cancer care that can improve patient outcomes. For more information, visit www.Kiyatec.com.

For more details about Kiyatec’s 3D Predict tests or to schedule an interview, please contact Eric Perreault at [e-mail].

©2025 Kiyatec. All Rights Reserved. KYT39-V1-0125